GlassScriptPhysician profile
Tanya D Perich
NPI 1750661666
$67,698.93
in general payments reported to CMS, 2019-2025
33 companies · $63K in 2025
The $63K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $404 · 2021: $1,046 · 2022: $1,292 · 2023: $274 · 2024: $297 · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $63K · Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $63,295.42 |
| Food and Beverage | $735.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $63,461.98 | 2019-2025 | Rocklatan |
| Notal Vision, INC. | $535.93 | 2022 | |
| Allergan, INC. | $485.33 | 2019-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $426.48 | 2021-2022 | |
| Horizon Therapeutics Plc | $364.34 | 2020-2022 | |
| Merz North America, INC. | $332.50 | 2019-2025 | |
| Abbvie INC. | $210.14 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $208.60 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $201.02 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $197.26 | 2021-2023 | Acthar |
| Sun Pharmaceutical Industries INC. | $196.24 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $145.07 | 2023-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $105.43 | 2019-2023 | |
| Amgen INC. | $99.07 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $95.02 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $72.65 | 2021-2024 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $71.09 | 2023-2024 | Ifs Advanced Femtosec Laser, Catalys System, Veritas Vision System |
| Shire North American Group INC | $67.72 | 2019 | |
| Bausch & Lomb Americas INC. | $61.18 | 2023-2024 | Vyzulta, Stellaris, Xiidra |
| Smith+Nephew, INC. | $59.58 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $44.55 | 2024 | Xdemvy |
| Mallinckrodt Enterprises LLC | $33.26 | 2019 | |
| New World Medical,INC. | $33.26 | 2024-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Oyster Point Pharma, INC. | $28.88 | 2022-2023 | Tyrvaya |
| Galderma Laboratories, L.P. | $25.67 | 2021 | |
| Revance Therapeutics, INC. | $24.82 | 2025 | Daxxify |
| Thea Pharma INC. | $22.77 | 2024 | Iyuzeh |
| Apellis Pharmaceuticals, INC. | $20.06 | 2023 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $18.91 | 2024 | Eylea Hd |
| Antares Pharma, INC. | $16.92 | 2022 | |
| Dompe US, INC. | $13.26 | 2019 | |
| Eyevance Pharmaceuticals LLC | $10.87 | 2019 | |
| Apyx Medical Corporation | $9.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Perich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.